For the quarter ending 2025-09-30, ARTV had -$2,960K decrease in cash & cash equivalents over the period. -$19,801K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,528 | -41,565 |
| Depreciation and amortization | 662 | 1,269 |
| Stock-based compensation | 1,631 | 3,601 |
| Accretion of discounts and amortization of premiums on investments, net | 357 | 1,232 |
| Other receivables (including related party amounts of (37) and (593), respectively) | 49 | -116 |
| Prepaid expenses and other current assets | -194 | 3,614 |
| Other long-term assets | 380 | -229 |
| Accounts payable (including related party amounts of (276) and 104, respectively) | -442 | -168 |
| Accrued expenses (including related party amounts of (702) and (854), respectively) | 1,119 | -1,481 |
| Operating lease right-of-use asset and lease liabilities, net | -51 | 21 |
| Net cash used in operating activities | -19,201 | -42,824 |
| Purchases of property and equipment | 600 | 1,566 |
| Purchases of investments | 12,745 | 24,591 |
| Maturities of investments | 29,623 | 57,250 |
| Net cash provided by (used in) investing activities | 16,278 | 31,093 |
| Proceeds from exercise of stock options | 0 | 138 |
| Proceeds from purchase of espp shares | -99 | -134 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | 104 | 39 |
| Payments on finance leases | 32 | 66 |
| Net cash provided by financing activities | -37 | 167 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -2,960 | -11,564 |
| Cash and cash equivalents at beginning of period | 40,493 | - |
| Cash and cash equivalents at end of period | 25,969 | - |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)